Novartis agreed to acquire global rights to Takeda's Xiidra (lifitegrast) for dry eye disease for $3.4B upfront plus up to $1.9B in potential milestones (~$5.3B total). Strengthens Novartis' eye-care portfolio. Post-close outcome: Novartis subsequently exited the asset. On June 30, 2023 Bausch + Lomb agreed to acquire Xiidra (along with libvatrep/SAF312, the AcuStream delivery device, and pre-clinical OJL332) from Novartis for up to $2.5B (USD 1.75B upfront cash plus up to USD 750M in sales/commercialization milestones); the divestment completed September 29, 2023 — roughly four years after Novartis paid up to $5.3B for the product.